LOS ANGELES–(BUSINESS WIRE)–The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Homology Medicines, Inc.. (“Homology” or “the Company”) (NASDAQ: FIXX) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Homology is the subject of a report published by Mariner Research on July 21, 2020. The report questions the efficacy of the Company’s lead product candidate, HMI-102. The report alleges that the company concealed efficacy information and predicted that the drug would not continue to commercialization. Based on this report, shares of Homology dropped by more than 10% on July 24, 2020.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at firstname.lastname@example.org.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.